Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling.
Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling.
复制标题
利用基于生理学的药代动力学模型，整合体外和体内模型预测纳米材料的细胞和组织剂量。
DOI：
10.1021/acsnano.2c07312
复制
发表时间：
2022-12-27
期刊：
影响因子：
17.1
通讯作者：
Gesquiere, Andre J.
中科院分区：
文献类型：
--
作者：
Lin, Zhoumeng;Aryal, Santosh;Cheng, Yi-Hsien;Gesquiere, Andre J.
关键词：
纳米材料（NM）已越来越多地用于许多领域，包括消费品和纳米医学。靶组织剂量测定在评价NM的安全性、有效性和潜在毒性方面很重要。目前对NM疗效和安全性的评价涉及耗时的动物药代动力学和毒性数据收集，通常一次完成一种材料。这种传统的方法已经不能满足基于纳米的产品爆炸式增长的需求。目前正在出现一种新的需要，即开发能够帮助以有效的方式设计安全和有效的国家管理系统的方法。在这篇综述文章中，我们严格评估现有的研究在体内药代动力学特性，在体外细胞摄取和释放和动力学建模，和全身生理为基础的药代动力学（PBPK）建模研究不同的NM。讨论了如何模拟体外细胞摄取和释放动力学以及如何通过PBPK模型将NM的细胞和组织剂量学从体外外推到体内的方法。我们还分享了我们对NM的体内药代动力学研究、体外细胞摄取和动力学建模以及全身PBPK建模研究的当前挑战和未来方向的看法。最后，我们提出了一种通过基于生理学的药代动力学模型（Nano−IVIVE−PBPK）框架进行纳米材料体外到体内外推的方法，用于高通量筛选靶细胞和组织剂量以及不同NM的潜在毒性，以满足快速增加的NM产品的安全性，有效性和潜在毒性的有效评估需求。
Nanomaterials (NMs) have been increasingly used in a number of areas, including consumer products and nanomedicine. Target tissue dosimetry is important in the evaluation of safety, efficacy, and potential toxicity of NMs. Current evaluation of NM efficacy and safety involves the time-consuming collection of pharmacokinetic and toxicity data in animals and is usually completed one material at a time. This traditional approach no longer meets the demand of the explosive growth of NM-based products. There is an emerging need to develop methods that can help design safe and effective NMs in an efficient manner. In this review article, we critically evaluate existing studies on in vivo pharmacokinetic properties, in vitro cellular uptake and release and kinetic modeling, and whole-body physiologically based pharmacokinetic (PBPK) modeling studies of different NMs. Methods on how to simulate in vitro cellular uptake and release kinetics and how to extrapolate cellular and tissue dosimetry of NMs from in vitro to in vivo via PBPK modeling are discussed. We also share our perspectives on the current challenges and future directions of in vivo pharmacokinetic studies, in vitro cellular uptake and kinetic modeling, and whole-body PBPK modeling studies for NMs. Finally, we propose a nanomaterial in vitro to in vivo extrapolation via physiologically based pharmacokinetic modeling (Nano−IVIVE−PBPK) framework for high-throughput screening of target cellular and tissue dosimetry as well as potential toxicity of different NMs in order to meet the demand of efficient evaluation of the safety, efficacy, and potential toxicity of a rapidly increasing number of NM-based products.
登录
查看更多内容
影响因子：
5.4
作者：
Bulbake U;Doppalapudi S;Kommineni N;Khan W
通讯作者：
Khan W
影响因子：
3.1
作者：
Torrano AA;Bräuchle C
通讯作者：
Bräuchle C
影响因子：
5
作者：
Bachler, Gerald;von Goetz, Natalie;Hungerbuhler, Konrad
通讯作者：
Hungerbuhler, Konrad
影响因子：
17.1
作者：
Au L;Zhang Q;Cobley CM;Gidding M;Schwartz AG;Chen J;Xia Y
通讯作者：
Xia Y
DOI：
10.1002/wnan.1808
发表时间：
2022-11
期刊：
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
影响因子：
--
作者：
通讯作者：
--